Skip to main content
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2026 Jul 28;17:1943610. doi: 10.3389/fphar.2026.1943610

Correction: Triglyceride-lowering therapies for hepatic steatosis: mechanisms, efficacy, and clinical perspectives

Seyed Saeed Tamehri Zadeh 1, Peter P Toth 2,3, Maciej Banach 3,4,*
PMCID: PMC13458186  PMID: 42582676

Affiliation International Lipid Expert Panel (ILEP), Lodz, Poland was omitted from the paper. This affiliation has now been added for author Seyed Saeed Tamehri Zadeh.

Affiliation Medical School, University of Western Australia, Perth, WA, Australia was erroneously included in the paper. This affiliation has now been removed for author Seyed Saeed Tamehri Zadeh.

The original version of this article has been updated.

Footnotes

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES